Tetrahydrocannabivarin (THCV) is an organic compound (cannabinoid) found most prevalently in Sativa strains of cannabis. It is believed to produce a more alert and energized euphoric feeling compared to THC, but for a shorter duration. At low doses, THCV blocks the CB1 receptor of the Endocannabinoid System, which means it’s not intoxicating. However, at high doses THCV has the opposite effect on CB1 receptors and will result in a euphoric sensation.
The Benefits of THCV
So, what are the health benefits of THCV? Most people don’t take it specifically to get high. So why is it being studied more? Research suggests that THCV may have multiple health benefits.
Anti-Inflammatory Effects
In a 2010 animal study, researchers investigated the effects of THCV on mice with chemically-induced inflammation. They found THCV was effective at reducing signs of swelling, inflammation, and pain. The researchers determined this effect was mediated through activation of both CB1 and CB2 receptors.
Weight Loss Effects
Studies have also indicated that THCV may be effective for weight loss. Research shows it suppresses the appetite for sweet taste and, at lower doses, demonstrates the ability to suppress appetite. In addition, regular administration of THCV in obese mice doesn’t modify food intake, but instead increases energy expenditure. Therefore, THCV may prove to be an effective weight loss supplement in addition to exercise and a healthy diet.
Blood Sugar Effects
Research also supports THCV in the treatment of diabetes. A study published in 2013 examined blood sugar levels in diet-induced obese mice and genetically obese mice. The study found THCV dose-dependently reduced glucose intolerance in genetically obese mice. Researchers also found THCV improved glucose tolerance and increased insulin sensitivity in diet-induced obese mice. Furthermore, THCV didn’t consistently affect cholesterol levels. The study concluded, “THCV is a new potential treatment against obesity-associated glucose intolerance.”
Additional Benefits
A 2011 study examined the effects of THCV in alleviating the symptoms and brain degeneration associated with Parkinson’s disease (PD). Mice with chemically induced models of PD were administered THCV both acutely and chronically. Results of the study found THCV, through its antioxidant properties and chronic administration, delayed the progression of PD. The researchers also observed improved parkinsonian symptoms in mice administered THCV even on a short-term basis.
Some Final Thoughts
THCV offers a variety of potential health benefits. However, limited access to high THCV strains (and cost) has hampered most cannabis companies from manufacturing THCV products. Most cannabis strains contain high levels of THC and/or CBD, but the levels of THCV are significantly lower. Nevertheless, the potential health benefits to humans of this cannabinoid can’t be ignored. Thus, there’s reason to believe in the near future that THCV will be featured in an increasing number of products.
References:
Wargent E et al; The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity; Nutrition & Diabetes; 2013 May; 3(5): e68.
Riedel G et al; Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice; British Journal of Pharmacology; 2009 Apr; 156(7): 1154-66.
Russo E; Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects; British Journal of Pharmacology; 2011 Aug; 163(7): 1344 – 1364.
Bolognini D et al; The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice; British Journal of Pharmacology; 2010 May; 160: 677 – 687.
Jadoon K et al; Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study; Diabetes Care; 2016 Oct; 39(10): 1777 – 1786.
Garcia C et al; Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease; British Journal of Pharmacology; 2011 Aug; 163(7): 1495 – 1506.
Rock E et al; Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats; British Journal of Pharmacology; 2013 Oct; 170(3): 671 – 678.
Pertwee R; The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin; British Journal of Pharmacology; 2008 Jan; 153(2): 199 – 215.
This content is for informational purposes only. It is not intended to take the place of medical advice or treatment from a personal physician. All readers of this content should consult their physician or qualified healthcare professional regarding specific health questions, especially those taking prescription or over-the-counter medications. CannaGlobe, LLC does not take responsibility for possible health consequences of any person reading and/or following this informational content.
